微生物的代谢物氧化酸通过与P2Y10受体的接触保持了先天性淋巴细胞的肠道组织存在
Yuwei Xu1, Zhen Xiong1, Peikang Zhang1,2
1State Key Laboratory of Epigenetic Regulation and Intervention, Institute of Biophysics, Chinese Academy of Sciences, Beijing, China.
Science advances
|August 22, 2025
概括
肠道微生物群的代谢物,如 taurodeoxycholic 酸 (TDCA),对于保持先天性淋巴细胞 (ILC) 在肠道组织中的存在至关重要. TDCA 增强了 ILC 的功能
科学领域:
- 免疫学
- 微生物学
- 胃肠病学
背景情况:
- 天生的淋巴细胞对免疫防御和组织健康至关重要.
- 控制ILCs在肠道组织中的存在机制尚未完全理解.
研究的目的:
- 阐明肠道微生物群在维持肠道ILC的作用.
- 为了确定特定的微生物代谢物和参与ILC肠道定位的受体.
主要方法:
- 研究了肠道微生物群对于ILC的必要性.
- 使用分子信号分析来识别 taurodeoxycholic 酸 (TDCA) -P2Y10受体相互作用.
- 评估了TDCA水平和P2Y10缺乏对ILC局部化和肠道炎症的影响.
主要成果:
- 肠道微生物群对于维持肠道组织中的ILCs至关重要.
- 微生物代谢物 taurodeoxycholic 酸 (TDCA) 与ILC上的P2Y10受体结合.
- TDCA-P2Y10信号通过Zfp414调节CD69和整合蛋白αE,促进ILC在肠道中的存在.
- 减少TDCA或P2Y10缺乏导致ILC损失和肠道炎症恶化.
结论:
- 肠道微生物代谢物,特别是TDCA,是ILC肠道组织存在的关键调节剂.
- TDCA-P2Y10通路是维持肠道ILC的一个关键机制.
- 通过增强ILC,TDCA对炎症性肠病具有治疗潜力.
相关概念视频
Inflammatory Bowel Disease IV: Pharmacological Management
189
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
189
Drugs Affecting GI Tract Motility: Adsorbents as Antidiarrheal Agents
317
Diarrhea is characterized by the occurrence of frequent, watery bowel movements. Various factors can trigger diarrhea, including viral or bacterial infections, foodborne illnesses, side effects from certain medications, and underlying digestive disorders. If not adequately managed, diarrhea can lead to complications such as dehydration, electrolyte imbalances, and nutrient deficiencies. Severe diarrhea can lead to significant weight loss, malnutrition, and weakened immune function.
Adsorbents...
Adsorbents...
317
Renewal of Intestinal Stem Cells
2.7K
The intestinal epithelial lining rapidly renews every 4 to 5 days. The renewal is facilitated by intestinal stem cells (ISCs) located at the base of the crypt– a gland located at the bottom of each villus. ISCs divide asymmetrically to form new stem cells and progenitor daughter cells. The daughter cells are called transit-amplifying (TA) cells which move upwards along the crypt and either differentiate into absorptive cells– the enterocytes or secretory cells– including the...
2.7K
Drugs for Treatment of Diarrhea-Predominant IBS
292
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
292
Drugs for Treatment of Ulcerative Colitis in IBD
236
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
236
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
267
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
267


